The flowchart above depicts the preclinical testing screening strategy. Only models that have been phenotypically validated to demonstrate LOAD-like endophenotypes (see Disease Modeling Project) will enter the primary screen. Each phase has a predetermined Go/No Go criteria that must be met before moving to the next phase.
Recent Posts
- AD Knowledge Portal Data Release 17.5
- A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease
- Molecular estimation of neurodegeneration pseudotime in older brains
- Model organism development and evaluation for late-onset Alzheimer’s disease: MODEL-AD
- MODEL-AD Publications June-July 2020